Summary

Fc and Glycoengineered Antibodies Market (4th Edition): Industry Trends and Global Forecasts, Till 2035 - Type of Engineering (Fc Engineering and Glycoengineering), Type of Therapy (Monotherapy, Combination Therapy and Both), Therapeutic Area (Oncological Disorders, Dermatological Disorders, Autoimmune Disorders, Rare Disorders and Other Disorders), Route of Administration (Intravenous, Subcutaneous and Intramuscular) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World) and Sales Forecast
Report Link: https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html
The Fc and Glycoengineered Antibodies market is expected to reach USD 38.8 billion by 2024 anticipated to grow at a CAGR of XX% during the forecast period 2024-2035.
The biopharmaceutical industry is witnessing surge in antibody-based pharmacology, marked by the approval of more than 120 monoclonal antibodies owing to their therapeutic use and about 900 clinical trials underway for further assessment. These progressions indicate a significant potential contribution to global sales by 2025 in this domain. The effectiveness of these drug therapies is dependent on the outcome of these drugs for a specific disease. Drugs demonstrating high therapeutic efficacy enhances the treatment outcomes by targeting specificity, minimizing side effects, and enhanced duration of action. To improve the therapeutic efficacy of these antibodies, recent advancements have been focusing on several Fc and glycoengineering strategies. These strategies aim to enhance the effector functions, such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity, while also extending the antibody's half-life through Fc region modifications. Glycoengineering, on the other hand, optimizes pharmacokinetic and pharmacodynamic properties by controlling glycan composition. Engineered antibodies are particularly valuable for augmenting the anti-tumor potential of monoclonal antibodies.

Currently, several drug developers and technology providers in this domain are actively involved in developing Fc and glycoengineered antibodies. Major pharmaceutical companies are showing increased interest and making substantial investments in this domain. Over the globe, over 150 Fc and glycoengineered antibodies have been approved till date, with recent examples including Retifanlimab, Elranatamab, Glofitamab, and Tislelizumab in 2023. Given the promising pipeline of antibody-based drugs, ongoing technological advancements, and enhanced interest from biopharmaceutical developers, substantial market growth is expected in the Fc and glycoengineered antibodies sector during the forecast period.
Research Coverage:
A detailed overview of the antibodies, including projections on anatomical of the antibodies, history of the antibody discovery, isotypes of antibodies, mechanism of action of antibodies. Further, it presents a brief description of the Fc region and effector functions, type of Fc receptors, engineering of the region along with the information on glycoengineering, protein engineering and isotype chimerism. Moreover, it provides an overview of the future perspectives, which, we believe, are likely to influence the growth of the Fc and glycoengineered antibodies market.
A comprehensive evaluation of more than 170 marketed / development programs, formulated for the treatment for various indications, presenting a detailed evaluation of the Fc and glycoengineered antibodies, based on key parameters, such as phase of development (marketed, clinical and preclinical), type of antibody (IgG1, IgG2, IgG2/4 and others), type of engineering (Fc engineering and glycoengineering), impact of engineering (enhanced effector function, reduced effector function and enhanced serum half-life), biological target (CD20, CD30, PD-L1 and others), type of therapy (monotherapy and combination therapy), target disease indication, therapeutic area (autoimmune disorders, infectious diseases, oncological disorders and others), route of administration (intravenous, subcutaneous and others), and popular Fc engineering technologies.
Comprehensive profiles of leading players (shortlisted based on our proprietary criteria) involved in the development of Fc engineered antibodies. Each profile presents a brief overview of the company (including information on year of establishment, location of headquarters, number of employees and leadership team), financial information (if available), drug portfolio, recent developments and an informed future outlook.
A comprehensive analysis of the ongoing, completed and planned clinical studies evaluating the Fc and glycoengineered antibodies, on the several prominent parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor, most active industry players (in terms of number of trials conducted), study design, target indication and key geographical regions.
An exhaustive evaluation of the partnerships signed between several stakeholders engaged in this domain, since 2016, based on several key parameters, such as year of partnership, type of partnership, type of engineering, therapeutic area and the most active players (in terms of the number of partnerships signed). Further, it presents insights pertaining to the partnership activity in this domain, based on the regional distribution of the players engaged in these agreements.
Exhaustive evaluation of the grants awarded to several research institutes for the projects related to Fc and glycoengineered antibodies, during the given time period 2019 to 2024 (till February), based on several key parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, most popular NIH departments, prominent program officers, popular recipient organizations.
A detailed analysis of patents that have been filed / granted related to Fc and glycoengineering antibodies, based on type of patent (granted patents, patent applications and others), publication year, application year, type of applicant, geographical location, CPC symbols and most active players (in terms of the number of patents filed / granted). In addition, this chapter presents patent benchmarking and an elaborate patent valuation analysis, presenting the leading patents (in terms of number of citations).
A comprehensive analysis of the Fc and glycoengineered antibodies market forecast is provided in order further to evaluate the current market size and future opportunity over the next 11 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided informed estimates on the market size during the forecast period, 2024-2035.
Detailed evaluations on the current and future opportunity within the Fc and glycoengineered antibodies market based on different types of engineering, such as Fc engineered antibodies and glycoengineered antibodies.
Comprehensive projections of the current and future opportunity within the Fc and glycoengineered antibody market segregated based on the different types of therapy, such as monotherapy, combination therapy and both.
Exhaustive estimated on the current and future Fc and glycoengineered antibodies market across different therapeutic areas, such as oncological disorders, rare disorders, dermatological disorders, autoimmune disorders and other disorders.
Comprehensive projections of the current and future opportunity within the Fc and glycoengineered antibody market based on different routes of administration, such as intravenous, subcutaneous and intramuscular routes of administration.
Detailed projections of the current and future opportunity within the Fc and glycoengineered antibodies market segmented based on the key geographical regions, such as North America, Europe, Asia-Pacific and Rest of the World.
Detailed projections of the current and future revenues generated from the sales of the marketed and phase III drugs in the Fc and glycoengineered antibodies domain.
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the Fc and Glycoengineered Antibodies Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
AbbVie
Akesobio
Alexion Pharmaceuticals
Amgen
AstraZeneca
Boehringer Ingelheim
Genentech
MacroGenics
MorphoSys
Kyowa Kirin
Xencor

ページTOPに戻る

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2 RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation

2.7. Key Market Segmentations

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.2.3. Foreign Exchange Impact
3.2.2.4. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.2.5. Strategies for Mitigating Foreign Exchange Risk

3.2.3. Recession
3.2.3.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.3.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.4. Inflation
3.4.4.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.4.4.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY
4.1. Chapter Overview

5. INTRODUCTION
5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. Historical Timeline of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Fc Region and Effector Functions
5.6.1. Types of Fc Receptors
5.6.2. Engineering of the Fc Region
5.6.2.1. Glycoengineering
5.6.2.2. Protein Engineering
5.6.2.3. Isotype Chimerism

5.7. Future Perspective

6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Fc Engineered and Glycoengineered Antibodies: Overall Pipeline
6.2.1. Analysis by Stage of Development
6.2.2. Analysis by Type of Antibody
6.2.3. Analysis by Type of Engineering
6.2.4. Analysis by Impact of Engineering
6.2.5. Analysis by Biological Target
6.2.6. Analysis by Type of Therapy
6.2.7. Analysis by Target Disease Indication
6.2.8. Analysis by Therapeutic Area
6.2.9. Analysis by Route of Administration
6.2.10. Popular Fc Engineering Technologies: Analysis by Number of Marketed Drugs and Development Programs

6.3. Fc Engineered and Glycoengineered Antibodies: Overall Developer Landscape
6.3.1 Analysis by Year of Establishment
6.3.2 Analysis by Company Size
6.3.3 Analysis by Location of Headquarters
6.3.4. Leading Developers: Analysis by Number of Drugs

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Detailed Company Profiles of Leading Fc Engineered and Glycoengineered Antibody Drug Developers
7.2.1. AbbVie
7.2.1.1. Company Overview
7.2.1.2. Financial Information
7.2.1.3. Drug Portfolio
7.2.1.3.1. Drug Profile: Skyrizi
7.2.1.4. Recent Developments and Future Outlook

7.2.2. Alexion Pharmaceuticals
7.2.2.1. Company Overview
7.2.2.2. Drug Portfolio
7.2.2.2.1. Drug Profile: Soliris
7.2.2.2.2. Drug Profile: Ultomiris
7.2.2.3. Recent Developments and Future Outlook

7.2.3. AstraZeneca
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Drug Portfolio
7.2.3.3.1. Drug Profile: Beyfortus
7.2.3.3.2. Drug Profile: Imfinzi
7.2.3.3.3. Drug Profile: Fasenra
7.2.3.3.4. Drug Profile: Saphnelo
7.2.3.4. Recent Developments and Future Outlook

7.2.4. Genentech
7.2.4.1. Company Overview
7.2.4.2. Financial Information
7.2.4.3. Drug Portfolio
7.2.4.3.1. Drug Profile: Gazyva
7.2.4.3.2. Drug Profile: Ocrevus
7.2.4.3.3. Drug Profile: Tecentriq
7.2.4.4. Recent Developments and Future Outlook

7.2.5. MacroGenics
7.2.5.1. Company Overview
7.2.5.2. Financial Information
7.2.5.3. Drug Portfolio
7.2.5.3.1. Drug Profile: Margenza
7.2.5.3.2. Drug Profile: MGA-271
7.2.5.4. Recent Developments and Future Outlook

7.2.6. Kyowa Kirin
7.2.6.1. Company Overview
7.2.6.2. Financial Information
7.2.6.3. Drug Portfolio
7.2.6.3.1. Drug Profile: POTELIGEO
7.2.6.4. Recent Developments and Future Outlook

7.3. Short Company Profiles of Leading Fc Engineered and Glycoengineered Antibody Drug Developers
7.3.1. Akeso Biopharma
7.3.1.1. Company Overview
7.3.1.2. Drug Portfolio
7.3.1.2.1. Drug Profile: Penpulimab

7.3.2. Amgen
7.3.2.1. Company Overview
7.3.2.2. Drug Portfolio
7.3.2.2.1. Drug Profile: Bemarituzuman
7.3.2.2.2. Drug Profile: STEAP1 XmAb Antibody
7.3.2.2.3. Drug Profile: FPA157

7.3.3. Boehringer Ingelheim
7.3.3.1. Company Overview
7.3.3.2. Drug Portfolio
7.3.3.2.2. Drug Profile: Spesolimab

7.3.4. MorphoSys
7.3.4.1. Company Overview
7.3.4.2. Drug Portfolio
7.3.4.2.1. Drug Portfolio: Tafasitamab

7.3.5. Xemcor
7.3.5.1. Company Overview
7.3.5.2. Drug Portfolio
7.3.5.2.1. Drug Portfolio: Tidutamab
7.3.5.2.2. Drug Portfolio: XmAb22841
7.3.5.2.3. Drug Portfolio: XmAb23104
7.3.5.2.4. Drug Portfolio: Plamotamab
7.3.5.2.5. Drug Portfolio: Vibecotamab
7.3.5.2.6. Drug Portfolio: RO7310729
7.3.5.2.7. Drug Portfolio: XmAb20717
7.3.5.2.8. Drug Portfolio: XmAb819
7.3.5.2.9. Drug Portfolio: XmAb27564
7.3.5.2.10. Drug Portfolio: VRC01LS

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Fc Engineered and Glycoengineered Antibodies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
8.3.3. Analysis by Trial Phase
8.3.4. Analysis of Number of Patients Enrolled by Trial Phase
8.3.5. Analysis by Trial Registration Year and Trial Phase
8.3.6. Analysis by Trial Status
8.3.7. Analysis by Patient Gender
8.3.8. Analysis by Target Indication

8.3.9. Analysis by Study Design
8.3.9.1. Analysis by Type of Trial Masking
8.3.9.2. Analysis by Type of Intervention Model
8.3.9.3. Analysis by Type of Trial Purpose
8.3.9.4. Analysis by Design Allocation

8.3.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
8.3.10.1. Analysis by Leading Industry Players
8.3.10.2. Analysis by Leading Non-Industry Players

8.3.11. Analysis by Geography
8.3.11.1. Analysis of Clinical Trials by Trial Status and Geography
8.3.11.2. Analysis of Patients Enrolled by Trial Status and Geography

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Fc Engineered and Glycoengineered Antibodies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Engineering
9.3.5. Analysis by Therapeutic Area
9.3.6. Most Active Players: Analysis by Number of Partnerships

9.3.7. Analysis by Geography
9.3.7.1. Intracontinental and Intercontinental Agreements
9.3.7.2. Local and International Agreements

10. GRANT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Fc Engineered and Glycoengineered Antibodies: Grant Analysis
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Amount Awarded
10.3.3. Analysis by Funding Institute Center
10.3.4. Analysis by Support Period
10.3.5. Analysis by Funding Institute Center and Support Period
10.3.6. Analysis by Type of Grant Application
10.3.7. Analysis by Purpose of Grant Award
10.3.8. Analysis by Activity Code
10.3.9. Analysis by Study Section Involved

10.3.10. Most Popular NIH Departments: Analysis by Number of Grants
10.3.10.1. Prominent Program Officers: Analysis By Number of Grants
10.3.10.2. Popular Recipient Organizations: Analysis by Number of Grants
10.3.10.3. Popular Recipient Organizations: Analysis by Grant Amount
10.3.11. Popular Recipient Organizations: Distribution by States in the US

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Fc Engineered and Glycoengineered Antibodies: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis by Patent Application Year
11.3.3. Analysis by Granted Patents and Patent Applications, 2019-2023
11.3.4. Analysis by Patent Jurisdiction
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Type of Applicant
11.3.7. Leading Industry Players: Analysis by Number of Patents
11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
11.3.9. Leading Patent Assignees: Analysis by Number of Patents

11.3.10. Patent Benchmarking Analysis
11.3.10.1. Analysis by Patent Characteristics

11.3.11. Patent Valuation
11.3.12. Leading Patents by Number of Citations

12. GLOBAL Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Global Fc Engineered and Glycoengineered Antibodies Market, Historical Trends (2019-2023) and Future Estimates (2024-2035)
12.3.1. Scenario Analysis
12.3.1.1. Conservative Scenario
12.3.1.2. Optimistic Scenario

12.4. Key Market Segmentations

13. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY TYPE OF ENGINEERING
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Engineering, 2024 and 2035
13.3.1. Fc Engineered Antibodies Market, 2024-2035
13.3.2. Glycoengineered Antibodies Market, 2024-2035

13.4. Data Triangulation and Validation

14. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY TYPE OF THERAPY
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Therapy, 2024 and 2035
14.3.1. Fc Engineered and Glycoengineered Market for Monotherapy, 2024-2035
14.3.2. Fc Engineered and Glycoengineered Market for Combination Therapy, 2024-2035
14.3.3. Fc Engineered and Glycoengineered Market for Both, 2024-2035

14.4. Data Triangulation and Validation

15. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY THERAPEUTIC AREA
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Therapeutic Area, 2024 and 2035
15.3.1. Fc Engineered and Glycoengineered Market for Oncological Disorders, 2024-2035
15.3.2. Fc Engineered and Glycoengineered Market for Dermatological Disorders, 2024-2035
15.3.3. Fc Engineered and Glycoengineered Market for Autoimmune Disorders, 2024-2035
15.3.4. Fc Engineered and Glycoengineered Market for Rare Disorders, 2024-2035
15.3.4. Fc Engineered and Glycoengineered Market for Other Disorders, 2024-2035

15.4. Data Triangulation and Validation

16. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Route of Administration, 2024 and 2035
16.3.1. Fc Engineered and Glycoengineered Market for Intravenous Route, 2024-2035
16.3.2. Fc Engineered and Glycoengineered Market for Subcutaneous Route, 2024-2035
16.3.3. Fc Engineered and Glycoengineered Market for Intramuscular Route, 2024-2035

16.4. Data Triangulation and Validation

17. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY KEY GEOGRAPHICAL REGIONS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Key Geographical Regions, 2024 and 2035
17.3.1. Fc Engineered and Glycoengineered Market in North America, 2024-2035
17.3.2. Fc Engineered and Glycoengineered Market in Europe, 2024-2035
17.3.3. Fc Engineered and Glycoengineered Market in Asia-Pacific, 2024-2035
17.3.4. Fc Engineered and Glycoengineered Market in Rest of the World, 2024-2035

17.4. Data Triangulation and Validation

18. Fc ENGINEEREDAND GLYCOENGINEERED ANTIBODIES MARKET, SALES FORECAST OF DRUGS
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Sales Forecast
18.3.1. AK-105 Sales Forecast
18.3.2. BeyfortusTM Sales Forecast
18.3.3. Briumvi® Sales Forecast
18.3.4. Fasenra® Sales Forecast
18.3.5. Gazyva® Sales Forecast
18.3.6. Imfinzi® Sales Forecast
18.3.7. Margenza Sales Forecast
18.3.8. Monjuvi® Sales Forecast
18.3.9. Ocrevus® Sales Forecast
18.3.10. POTELIGEO® Sales Forecast
18.3.11. Saphnelo® Sales Forecast
18.3.12. Skyrizi® Sales Forecast
18.3.13. Soliris® Sales Forecast
18.3.14. Tecentriq® Sales Forecast
18.3.15. Tislelizumab Sales Forecast
18.3.16. Tzield® Sales Forecast
18.3.17. Ultomiris® Sales Forecast
18.3.18. Uplizna® Sales Forecast

18.4. Phase III Fc Engineered and Glycoengineered Antibodies Market: Sales Forecast
18.4.1. Clazakizumab Sales Forecast
18.4.2. FPA144 Sales Forecast
18.4.3. Skyrizi Sales Forecast
18.4.4. TQ-B2450 Sales Forecast
18.4.5. Visterra Sales Forecast

18.6. Data Triangulation and Validation

19. CONCLUDING REMARKS
19.1. Chapter Overview

20 APPENDIX I: TABULATED DATA

21 APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

List of Tables/Graphs

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1. Lessons Learnt from Past Recessions
Figure 4.1. Executive Summary: Overall Market Landscape
Figure 4.2. Executive Summary: Clinical Trial Analysis
Figure 4.3. Executive Summary: Partnerships and Collaborations
Figure 4.4. Executive Summary: Grant Analysis
Figure 4.5. Executive Summary: Patent Analysis
Figure 4.6. Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1. Structure of an Antibody
Figure 5.2. Historical Timeline of Antibody Development
Figure 5.3. Main Functions of Antibodies
Figure 6.1. Fc Engineered and Glycoengineered Antibodies: Distribution by Stage of Development
Figure 6.2. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Antibody
Figure 6.3. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Engineering
Figure 6.4. Fc Engineered and Glycoengineered Antibodies: Distribution by Impact of Engineering
Figure 6.5. Fc Engineered and Glycoengineered Antibodies: Distribution by Biological Target
Figure 6.6. Fc Engineered and Glycoengineered Antibodies: Distribution by Type of Therapy
Figure 6.7. Fc Engineered and Glycoengineered Antibodies: Distribution by Target Disease Indication
Figure 6.8. Fc Engineered and Glycoengineered Antibodies: Distribution by Therapeutic Area
Figure 6.9. Fc Engineered and Glycoengineered Antibodies: Distribution by Route of Administration
Figure 6.10. Popular Fc Engineered Technologies: Distribution by Number of Marketed Drugs Development Programs
Figure 6.11. Fc Engineered and Glycoengineered Antibodies: Distribution by Year of Establishment
Figure 6.12. Fc Engineered and Glycoengineered Antibodies: Distribution by Company Size
Figure 6.13. Fc Engineered and Glycoengineered Antibodies: Distribution by Location of Headquarters
Figure 6.14. World Map Representation: Analysis by Geography
Figure 6.15. Leading Developers: Distribution by Number of Drugs
Figure 7.1. AbbVie: Annual Revenues, FY 2019-FY 2023 (USD Billion)
Figure 7.2. AstraZeneca: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Figure 7.3. Roche (Parent Company of Genentech): Annual Revenues, FY 2019 - FY 2023 (CHF Billion)
Figure 7.4. MacroGenics: Annual Revenues, FY 2019 - 9M FY 2023 (USD Million)
Figure 7.5. Kyowa Kirin: Annual Revenues, FY 2019 - FY 2023 (YEN Billion)
Figure 8.1. Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2015-2024
Figure 8.2. Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Pre-2015-2024
Figure 8.3. Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4. Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 8.5. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2015–2024
Figure 8.6. Clinical Trial Analysis: Distribution by Trial Status
Figure 8.7. Clinical Trial Analysis: Distribution by Patient Gender
Figure 8.8. Clinical Trial Analysis: Distribution by Target Indication
Figure 8.9. Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 8.10. Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 8.11. Clinical Trial Analysis: Distribution by Trial Purpose
Figure 8.12. Clinical Trial Analysis: Distribution by Design Allocation
Figure 8.13. Leading Industry Players: Distribution by Number of Registered Trials
Figure 8.14. Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.15. Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 8.16. Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2024
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4. Partnerships and Collaborations: Distribution by Type of Engineering
Figure 9.5. Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.6. Most Active Players: Distribution by Number of Partnerships
Figure 9.7. Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 9.8. Partnerships and Collaborations: Local and International Agreements
Figure 10.1. Grant Analysis: Cumulative Year-wise Trend, 2019-2024
Figure 10.2. Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
Figure 10.3. Grants Analysis: Distribution by Funding Institute Center
Figure 10.4. Grants Analysis: Distribution by Support Period
Figure 10.5. Grants Analysis: Distribution by Funding Institute Center and Support Period
Figure 10.6. Grants Analysis: Distribution by Type of Grant Application
Figure 10.7. Grants Analysis: Distribution by Purpose of Grant Award
Figure 10.8. Grants Analysis: Distribution by Activity Code
Figure 10.9. Grants Analysis: Distribution by Study Section Involved
Figure 10.10. Most Popular Departments: Distribution by Number of Grants
Figure 10.11. Prominent Program Officers: Distribution by Number of Grants
Figure 10.12. Popular Recipient Organizations: Distribution by Number of Grants
Figure 10.13. Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Figure 10.14. Popular Recipient Organizations: Distribution by States in the US
Figure 11.1. Patent Analysis: Distribution by Type of Patent
Figure 11.2. Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2024
Figure 11.3. Patent Analysis: Distribution by Patent Application Year, Pre-2019-2023
Figure 11.4. Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
Figure 11.5. Patent Analysis: Distribution by Patent Jurisdiction
Figure 11.6. Patent Analysis: Distribution by CPC Symbols
Figure 11.7. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 11.8. Leading Industry Players: Distribution by Number of Patents
Figure 11.9. Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10. Leading Individual Assignees: Distribution by Number of Patents
Figure 11.11. Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 11.12. Patent Benchmarking Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 11.13. Patent Analysis: Distribution by Patent Age
Figure 11.14. Fc Engineered and Glycoengineered Antibodies: Patent Valuation
Figure 12.1. Global Fc Engineered and Glycoengineered Antibodies Market, Historical Trends (2019-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 12.2. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Conservative Scenario (USD Billion)
Figure 12.3. Global Fc Engineered and Glycoengineered Antibodies Market, 2024-2035: Optimistic Scenario (USD Billion)
Figure 13.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Engineering,2024 and 2035
Figure 13.2. Fc Engineered and Glycoengineered Antibodies Market for Fc Engineered Antibodies, 2024-2035 (USD Billion)
Figure 13.3. Fc Engineered and Glycoengineered Antibodies Market for Glycoengineered Antibodies, 2024-2035 (USD Billion)
Figure 14.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Therapy, 2024 and 2035
Figure 14.2. Fc Engineered and Glycoengineered Antibodies Market for Monotherapy, 2024-2035 (USD Billion)
Figure 14.3. Fc Engineered and Glycoengineered Antibodies Market for Combination Therapy, 2024-2035 (USD Billion)
Figure 14.4. Fc Engineered and Glycoengineered Antibodies Market for Both, 2024-2035 (USD Billion)
Figure 15.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Therapeutic Area, 2024 and 2035
Figure 15.2. Fc Engineered and Glycoengineered Antibodies Market for Oncological Disorders, 2024-2035 (USD Billion)
Figure 15.3. Fc Engineered and Glycoengineered Antibodies Market for Dermatological Disorders, 2024-2035 (USD Billion)
Figure 15.4. Fc Engineered and Glycoengineered Antibodies Market for Autoimmune Disorders, 2024-2035 (USD Billion)
Figure 15.5. Fc Engineered and Glycoengineered Antibodies Market for Rare Disorders, 2024-2035 (USD Billion)
Figure 15.6. Fc Engineered and Glycoengineered Antibodies Market for Other Disorders, 2024-2035 (USD Billion)
Figure 16.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Route of Administration, 2024 and 2035
Figure 16.2. Fc Engineered and Glycoengineered Antibodies Market for Intravenous Route, 2024-2035 (USD Billion)
Figure 16.3. Fc Engineered and Glycoengineered Antibodies Market for Subcutaneous Route, 2024-2035 (USD Billion)
Figure 16.4. Fc Engineered and Glycoengineered Antibodies Market for Intramuscular Route, 2024-2035 (USD Billion)
Figure 17.1. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Key Geographical Regions, 2024 and 2035
Figure 17.2. Fc Engineered and Glycoengineered Antibodies Market in North America, 2024-2035 (USD Billion)
Figure 17.3. Fc Engineered and Glycoengineered Antibodies Market in Europe, 2024-2035 (USD Billion)
Figure 17.4. Fc Engineered and Glycoengineered Antibodies Market in Asia-Pacific, 2024-2035 (USD Billion)
Figure 17.5. Fc Engineered and Glycoengineered Antibodies Market in Rest of the World, 2024-2035 (USD Billion)
Figure 18.1. Commercialized Fc Engineered and Glycoengineered Antibodies Market: AK-105 Sales Forecast, 2021-2035 (USD Billion)
Figure 18.2. Commercialized Fc Engineered and Glycoengineered Antibodies Market: BeyfortusTM Sales Forecast, 2022-2035 (USD Billion)
Figure 18.3. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Briumvi® Sales Forecast, 2023-2035 (USD Billion)
Figure 18.4. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Fasenra® Sales Forecast, 2018-2035 (USD Billion)
Figure 18.5. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Gazyva® Sales Forecast, 2017-2035 (USD Billion)
Figure 18.6. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Imfinzi® Sales Forecast, 2018-2035 (USD Billion)
Figure 18.7. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Margenza Sales Forecast, 2021-2035 (USD Billion)
Figure 18.8. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Monjuvi® Sales Forecast, 2020-2035 (USD Billion)
Figure 18.9. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ocrevus® Sales Forecast, 2017-2035 (USD Billion)
Figure 18.10. Commercialized Fc Engineered and Glycoengineered Antibodies Market: POTELIGEO® Sales Forecast, 2019-2035 (USD Billion)
Figure 18.11. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Saphnelo® Sales Forecast, 2021-2035 (USD Billion)
Figure 18.12. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Skyrizi® Sales Forecast, 2020-2035 (USD Billion)
Figure 18.13. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Soliris® Sales Forecast, 2017-2035 (USD Billion)
Figure 18.14. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tecentriq® Sales Forecast, 2017-2035 (USD Billion)
Figure 18.15. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tislelizumab Sales Forecast, 2020-2035 (USD Billion)
Figure 18.16. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Tzield® Sales Forecast, 2023-2035 (USD Billion)
Figure 18.17. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Ultomiris® Sales Forecast, 2019-2035 (USD Billion)
Figure 18.18. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Uplizna® Sales Forecast, 2020-2035 (USD Billion)
Figure 18.19. Phase III Fc Engineered and Glycoengineered Antibodies Market: Clazakizumab Sales Forecast, 2030-2035 (USD Billion)
Figure 18.20. Phase III Fc Engineered and Glycoengineered Antibodies Market: FPA144 Sales Forecast, 2027-2035 (USD Billion)
Figure 18.21. Phase III Fc Engineered and Glycoengineered Antibodies Market: Skyrizi Sales Forecast, 2024-2035 (USD Billion)
Figure 18.22. Phase III Fc Engineered and Glycoengineered Antibodies Market: TQ-B2450 Sales Forecast, 2027-2035 (USD Billion)
Figure 18.23. Phase III Fc Engineered and Glycoengineered Antibodies Market: VIS649 Sales Forecast, 2028-2035 (USD Billion)
Figure 19.1. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Overall Market Landscape
Figure 19.2. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Clinical Trial Analysis
Figure 19.3. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Partnerships and Collaborations
Figure 19.4. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Grant Analysis
Figure 19.5. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Patent Analysis
Figure 19.6. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Market Sizing and Opportunity Analysis (I/II)
Figure 19.7. Concluding Remarks: Fc Engineered and Glycoengineered Antibodies: Market Sizing and Opportunity Analysis (II/II)